CureVac (NASDAQ:CVAC) Shares Gap Down – Here’s Why

Shares of CureVac (NASDAQ:CVAC) gapped down prior to trading on Friday . The stock had previously closed at $3.20, but opened at $3.13. CureVac shares last traded at $3.14, with a volume of 99,760 shares trading hands.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a report on Friday, February 14th.

CureVac Price Performance

The stock has a market capitalization of $690.67 million, a price-to-earnings ratio of 5.59 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The company has a 50-day simple moving average of $3.66 and a two-hundred day simple moving average of $3.20.

Institutional Investors Weigh In On CureVac

Hedge funds and other institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC acquired a new position in CureVac in the third quarter worth approximately $30,000. International Assets Investment Management LLC acquired a new stake in shares of CureVac during the 3rd quarter worth approximately $35,000. Integrated Wealth Concepts LLC bought a new stake in CureVac in the 3rd quarter valued at $35,000. Two Sigma Advisers LP acquired a new position in shares of CureVac in the 4th quarter valued at $48,000. Finally, Jump Financial LLC bought a new position in shares of CureVac in the fourth quarter valued at approximately $55,000. 17.26% of the stock is currently owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.